Forlisa Nauling

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

M. Ratain, C. Ng, R. Salgia, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.